Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPrescient Therapeutics Ltd

Prescient Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.063 AUD 0.00 ( 1.61%)
Last update at 2026-11-12T03:49:00Z
VOLUME
1237419
Market Cap
60.62M

Momentum Score

…

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.06
Low
0.07
High
52 Week Price Range
0.05
Low
0.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Prescient Therapeutics Ltd is a clinical-stage Australian biotechnology company focused on developing targeted cancer therapies through early- and mid‑stage clinical programs. Long-term growth drivers include progression of clinical trials, regulatory approvals or partnerships, and potential adoption in oncology indications with unmet need. Investors should monitor upcoming trial readouts and partnership activity because the company appears positioned to translate clinical data into value catalysts if trials deliver positive results.

The primary investment risks are high clinical and regulatory uncertainty, the likely need for additional financing, a competitive oncology landscape, and the possibility of trial setbacks or intellectual property challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.06
Dividend Yield
-
Revenue TTM
3.45M
Revenue Per Share
0.00
Gross Profit TTM
3.45M
Debt / Equity
0.02
ROE
-54.73%
Net Debt
-8.81M
ROCE
-73.98%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -10.44M -7.32M -11.95M -7.00M -5.12M
Net income -7.00M -7.32M -8.24M -7.00M -5.12M
Selling general administrative 5.31M 1.46M 1.49M 3.66M 3.70M
Selling and marketing expenses - 3.72M 2.43M - -
Gross profit -0.11M 4.36M 3.71M - -
Reconciled depreciation - 0.01M 0.00M 0.00M 0.00M
Ebit -10.59M -7.54M -7.19M -9.89M -5.11M
Ebitda -10.48M -7.54M -7.19M -9.89M -5.11M
Depreciation and amortization 0.11M 0.00M 0.00M 0.00M 0.00M
Operating income -10.59M -7.54M -7.19M -9.89M -5.11M
Other operating expenses 10.59M 11.89M 10.90M 9.89M 7.10M
Interest expense 0.01M - - - 0.01M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.14M 0.23M 0.69M 0.46M 0.04M
Net interest income 0.13M 0.23M 0.69M 0.46M 0.04M
Income tax expense -3.44M -4.36M -3.71M -0.46M 0.01M
Total revenue - 4.36M 3.71M 0.46M 0.04M
Total operating expenses 10.48M 11.89M 10.90M 9.89M 7.10M
Cost of revenue 0.11M - 0.00M - -
Total other income expense net 0.15M 0.21M -4.76M 2.42M -0.01M
Net income from continuing ops -7.00M -7.32M -8.24M -7.00M -5.12M
Net income applicable to common shares - -7.32M -8.24M -7.00M -5.12M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 16.28M 14.56M 20.39M 28.11M 17.62M
Intangible assets 1.65M 1.65M 1.65M 3.37M 3.37M
Other current assets 1.29M 4.65M 0.31M 2.37M 1.64M
Total liab 2.08M 3.17M 2.33M 2.03M 0.86M
Total stockholder equity 14.20M 11.39M 18.07M 26.08M 16.76M
Other current liab 0.95M - 0.27M 0.25M 0.30M
Common stock 102.79M - 93.27M 93.25M 77.26M
Capital stock 102.79M 93.89M 93.27M 93.25M 77.26M
Retained earnings -90.55M -84.07M -77.40M -69.31M -62.45M
Other liab - - - 0.01M 0.05M
Other assets - - 0.00M - -
Cash 9.03M 6.91M 10.49M 5.90M 12.26M
Cash and equivalents - - - 4.00M -
Total current liabilities 1.96M 3.16M 2.32M 2.03M 0.81M
Net debt -8.81M - -10.16M -5.90M -12.26M
Short term debt 0.11M - 0.33M 0.00M 0.00M
Short long term debt - - 0.33M - -
Short long term debt total 0.22M - 0.33M - -
Other stockholder equity - - - -23.93M -14.81M
Property plant equipment - - - 0.00M 0.00M
Total current assets 14.02M 12.90M 18.74M 24.74M 14.25M
Net tangible assets - - - 22.71M 13.40M
Short term investments 0.02M 0.02M 4.02M 16.02M 0.02M
Net receivables 3.70M 0.26M 3.92M 0.21M 0.08M
Inventory - - - 0.25M 0.24M
Accounts payable 0.90M 3.04M 1.72M 1.78M 0.51M
Accumulated other comprehensive income 1.96M - 2.19M 2.14M 1.95M
Non currrent assets other 0.39M - -0.00M -3.37M -3.37M
Non current assets total 2.26M 1.66M 1.65M 3.37M 3.37M
Capital lease obligations 0.22M - - - -
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 4.00M 12.00M -16.00M -0.00M
Change to liabilities - - - 1.16M 0.39M
Total cashflows from investing activities - 4.00M 12.00M -16.00M -0.00M
Net borrowings -0.10M -0.33M - - -0.17M
Total cash from financing activities 9.34M -0.33M 0.02M 15.83M 0.43M
Change to operating activities - - - -0.69M -0.39M
Net income -7.00M -7.32M -8.24M -7.00M -5.12M
Change in cash 2.12M -3.59M 4.60M -6.37M -3.83M
Begin period cash flow 6.91M 10.49M 5.90M 12.26M 16.10M
End period cash flow 9.03M 6.91M 10.49M 5.90M 12.26M
Total cash from operating activities -7.22M -7.24M -7.40M -6.19M -4.31M
Issuance of capital stock 10.12M - 0.02M 16.53M 0.59M
Depreciation 0.11M - 0.00M 0.00M 0.00M
Other cashflows from investing activities - 4.00M 12.00M - -
Change to account receivables 0.92M 0.54M -1.34M -0.13M -0.02M
Sale purchase of stock -0.68M 0.00M 0.02M - 0.59M
Other cashflows from financing activities 0.17M - -0.02M -0.70M -0.00M
Change to netincome - - - 0.47M 0.83M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -1.00M 0.05M -1.11M -0.13M -0.02M
Stock based compensation - - 0.21M 0.46M 0.88M
Other non cash items 0.67M -7.30M 1.95M 0.81M 0.80M
Free cash flow -7.22M -7.24M -7.40M -6.19M -4.32M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PTX
Prescient Therapeutics Ltd		 0.00
1.61%		 0.06 - 5.48 17.57 4.11 -8.36
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 -9.86

Profile*

Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Suite 2, Melbourne, VIC, Australia, 3000

61 3 9692 7222

https://ptxtherapeutics.com

Name Title Year Born
Mr. Steven Lee Yatomi-Clarke MD, CEO & Director NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA CFO & Company Sec. 1973
Ms. Leanne West Director of Clinical Affairs & Operations NA
Dr. Terrence G. Chew Chief Medical Officer 1947
Ms. Rebecca Lim Sr. VP of Scientific Affairs NA
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Rebecca Lim Senior Vice President of Scientific Affairs NA
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Rebecca Lim Senior Vice President of Scientific Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…